Bergen, Norway, 16 February 2022

The Board of Directors in BerGenBio ASA (the"Company") (OSE: BGBIO) have, to
fulfil the Company's obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, resolved to increase the Company's share capital by NOK 10,507.70 by
issuance of 105,277 new shares. The new shares are subscribed for by option
owners who wishes and are entitled to exercise options in accordance with the
Company's option scheme. Each option gives a right to receive one share in the
Company. The subscription price is in accordance with the prevailing options
price pursuant to the CompanyŽs option scheme, in average NOK 16.01 per share.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,866,053.20 consisting of 88,660,532, each with a par value of NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.